Buscar | Meisterbook

agregó una foto Health

2026-07-17 10:21:57 -

Neuroendocrine Carcinoma Market: How Is Lutetium-177 DOTATATE PRRT Becoming the Fastest-Growing Targeted Radiotherapy?

Lutetium-177 DOTATATE peptide receptor radionuclide therapy — the targeted radioligand delivering beta radiation to somatostatin receptor-expressing neuroendocrine tumors with 65-80% disease control rates and improved progression-free survival, now first-line for advanced gastroenteropancreatic NETs representing the fastest-growing targeted radiotherapy in the global neuroendocrine...

0 Commentarios 0 Acciones 8 Views 0 Vista previa